Savara Advances MOLBREEVI, Bolsters Commercial Team Ahead of PDUFA

Event summary

  • Savara reported a net loss of $32.2 million for Q4 2025, and $118.8 million for the full year 2025.
  • The company holds $235.7 million in cash and has access to up to $150 million in additional non-dilutive capital.
  • Savara filed a Biologics License Application (BLA) for MOLBREEVI and has an assigned PDUFA date of August 22, 2026.
  • A market development team is being onboarded, expected to be complete in Q2 2026, to prepare for commercial launch.

The big picture

Savara's progress on MOLBREEVI, particularly the BLA filing, positions the company as a potential leader in the treatment of Autoimmune PAP, a rare disease with limited therapeutic options. The company’s reliance on a single product creates inherent risk, but the substantial cash reserves and access to additional capital provide a buffer as they navigate the regulatory and commercialization phases. The rapid expansion of the commercial team signals a shift towards a more aggressive growth strategy.

What we're watching

Regulatory Risk
The August 2026 PDUFA date represents a critical inflection point; delays or rejection would significantly impact Savara's valuation and future prospects.
Commercial Execution
The success of MOLBREEVI’s launch will hinge on the effectiveness of the newly assembled market development team, and their ability to penetrate a niche market with a high price point.
Capital Needs
While Savara currently possesses substantial cash reserves, the costs associated with a global commercial launch could rapidly deplete these resources, potentially necessitating further capital raises.